Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma

C Santiskulvong, GE Konecny, M Fekete… - Clinical Cancer …, 2011 - AACR
Purpose: This study evaluates the effect of dual PI3K and mTOR inhibition using NVP-
BEZ235 in preclinical models of ovarian cancer as a potential novel therapeutic strategy …
被引用次数：129 相关文章
[PDF] academia.edu

[PDF][PDF] Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian …

C Santiskulvong, GE Konecny, M Fekete, KYM Chen… - academia.edu
Purpose: This study evaluates the effect of dual PI3K and mTOR inhibition using NVP-
BEZ235 in preclinical models of ovarian cancer as a potential novel therapeutic strategy …
[HTML] nih.gov

[HTML][HTML] Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian …

C Santiskulvong, GE Konecny, M Fekete… - … cancer research: an …, 2011 - ncbi.nlm.nih.gov
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using
NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma - PMC Back to …

Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma

C Santiskulvong, GE Konecny… - … : an official journal …, 2011 - pubmed.ncbi.nlm.nih.gov
Purpose This study evaluates the effect of dual PI3K and mTOR inhibition using NVP-
BEZ235 in preclinical models of ovarian cancer as a potential novel therapeutic strategy …

Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.

C Santiskulvong, GE Konecny, M Fekete… - … Cancer Research: an …, 2011 - europepmc.org
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235
as a novel therapeutic approach in human ovarian carcinoma. - Abstract - Europe PMC Sign …

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian …

C Santiskulvong, GE Konecny, M Fekete… - Clinical Cancer …, 2011 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Purpose: This study evaluates the effect of dual
PI3K and mTOR inhibition using NVP-BEZ235 in preclinical models of ovarian cancer as a …
[PDF] researchgate.net

[PDF][PDF] Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian …

C Santiskulvong, GE Konecny, M Fekete… - Clin Cancer …, 2011 - researchgate.net
Purpose—This study evaluates the effect of dual PI3K and mTOR inhibition using
NVPBEZ235 in preclinical models of ovarian cancer as a potential novel therapeutic …

[引用][C] Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian …

C SANTISKULVONG, GE KONECNY… - Clinical cancer …, 2011 - pascal-francis.inist.fr
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using
NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma CNRS Inist …

Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.

C Santiskulvong, GE Konecny, M Fekete… - … Cancer Research: an …, 2011 - europepmc.org
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235
as a novel therapeutic approach in human ovarian carcinoma. - Abstract - Europe PMC Sign …
[PDF] academia.edu

[PDF][PDF] Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian …

C Santiskulvong, GE Konecny, M Fekete, KYM Chen… - academia.edu
Purpose: This study evaluates the effect of dual PI3K and mTOR inhibition using NVP-
BEZ235 in preclinical models of ovarian cancer as a potential novel therapeutic strategy …